WallStSmart

Cellebrite DI (CLBT)vsVuzix Corp Cmn Stk (VUZI)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Cellebrite DI generates 8050% more annual revenue ($496.43M vs $6.09M). CLBT leads profitability with a 14.5% profit margin vs 0.0%. CLBT earns a higher WallStSmart Score of 40/100 (F).

CLBT

Hold

40

out of 100

Grade: F

Growth: 6.7Profit: 6.0Value: 3.0Quality: 6.5
Piotroski: 2/9Altman Z: 1.60

VUZI

Avoid

16

out of 100

Grade: F

Growth: 2.7Profit: 2.5Value: 6.7Quality: 7.0
Piotroski: 4/9Altman Z: -11.94
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

CLBTSignificantly Overvalued (-36.0%)

Margin of Safety

-36.0%

Fair Value

$10.92

Current Price

$14.57

$3.65 premium

UndervaluedFair: $10.92Overvalued
VUZIUndervalued (+40.2%)

Margin of Safety

+40.2%

Fair Value

$4.13

Current Price

$2.14

$1.99 discount

UndervaluedFair: $4.13Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CLBT2 strengths · Avg: 9.0/10
Debt/EquityHealth
0.0410/10

Conservative balance sheet, low leverage

Revenue GrowthGrowth
19.3%8/10

19.3% revenue growth

VUZI1 strengths · Avg: 10.0/10
Debt/EquityHealth
0.0310/10

Conservative balance sheet, low leverage

Areas to Watch

CLBT4 concerns · Avg: 2.8/10
Altman Z-ScoreHealth
1.604/10

Distress zone — elevated risk

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

P/E RatioValuation
54.9x2/10

Premium valuation, high expectations priced in

EPS GrowthGrowth
-42.9%2/10

Earnings declined 42.9%

VUZI4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$187.94M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Return on EquityProfitability
-90.3%2/10

ROE of -90.3% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : CLBT

The strongest argument for CLBT centers on Debt/Equity, Revenue Growth. Revenue growth of 19.3% demonstrates continued momentum.

Bull Case : VUZI

The strongest argument for VUZI centers on Debt/Equity.

Bear Case : CLBT

The primary concerns for CLBT are Altman Z-Score, Piotroski F-Score, P/E Ratio. A P/E of 54.9x leaves little room for execution misses.

Bear Case : VUZI

The primary concerns for VUZI are EPS Growth, Market Cap, Profit Margin.

Key Dynamics to Monitor

CLBT profiles as a growth stock while VUZI is a value play — different risk/reward profiles.

VUZI carries more volatility with a beta of 1.75 — expect wider price swings.

CLBT is growing revenue faster at 19.3% — sustainability is the question.

CLBT generates stronger free cash flow (17M), providing more financial flexibility.

Bottom Line

CLBT scores higher overall (40/100 vs 16/100) and 19.3% revenue growth. VUZI offers better value entry with a 40.2% margin of safety. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Cellebrite DI

TECHNOLOGY · SOFTWARE - INFRASTRUCTURE · USA

Cellebrite DI Ltd. provides digital intelligence solutions for the public and private sectors globally. The company is headquartered in Petah Tikva, Israel.

Vuzix Corp Cmn Stk

TECHNOLOGY · CONSUMER ELECTRONICS · USA

Vuzix Corporation designs, manufactures, markets and sells augmented reality (AR) computing and display devices for consumer and business markets in North America, Asia-Pacific, Europe, and internationally. The company is headquartered in West Henrietta, New York.

Want to dig deeper into these stocks?